Track topics on Twitter Track topics that are important to you
Dec 9 (Reuters) - Cara Therapeutics Inc said its arthritis drug met the main goal of reducing pain in patients in the first mid-stage study.
(Reuters) - Cara Therapeutics Inc said its arthritis drug met the main goal of reducing pain in patients in the first mid-stage study.
The US Food and Drug Administration (FDA) has removed the clinical hold on Cara Therapeutics' adaptive phase 3 clinical trial assessing an intravenous formulation (I.V.) of lead product candidate CR84...
MVM Life Science Partners closed its fourth fund, MVM IV, at $233 million. The firm said it will invest $15-$30 million per company in healthcare companies of all stages in the U.S. and Europe. MVM in...
Cara Therapeutics Inc. (NASDAQ:CARA) fell $2.91 (42%) to $4 in early after-hours trading after it said FDA placed a protocol clinical hold on its Phase III trial of IV CR845 to treat acute postoperati...
* Cara therapeutics announces removal of FDA clinical hold on clin3001 postoperative pain trial for i.v. Cr845
Pin-X Chewable Tablets PINWORMTREATMENT
We are experiencing a new wave of injectable therapeutics (namely/injectable biomaterials) to complement injectable drugs and injectable biologics, and to serve as the basis for injectable combinatori...
For any new class of therapeutics, there are certain types of indications that represent a natural fit. For nucleic acid ligands in general, and aptamers in particular, the eye has historically been a...
This study evaluates the effect of intake of two orange juice varieties in healthy adults. The participants will receive "Bahia" orange juice, "Cara-Cara" orange juice or a isocaloric cont...
The purpose of this study is to investigate a novel thermosensitive topical gel formulation for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis.
Among all racial/ethnic groups, African Americans have the greatest risk of becoming ill or dying from tobacco-related diseases. Because of this disproportionate disease burden, it is part...
Cara possesses both near-term clinical development opportunities, combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's first patented compound, CR665, has enter...
Me es grato darles la bienvenida a la página web del INSTITUTO DE CIRUGIA MAXILOFACIAL E IMPLANTOLOGIA.El Instituto, fundado en Mayo del 2000, tiene como objetivo el tratamiento integral médico-quir...
We have published hundreds of Cara Therapeutics, Inc. news stories on BioPortfolio along with dozens of Cara Therapeutics, Inc. Clinical Trials and PubMed Articles about Cara Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cara Therapeutics, Inc. Companies in our database. You can also find out about relevant Cara Therapeutics, Inc. Drugs and Medications on this site too.